DNL 921
Alternative Names: ATV Amyloid Beta - Denali Therapeutics; ATV-Amyloid-β - Denali Therapeutics; ATV-Aβ - Denali Therapeutics; DNL-921Latest Information Update: 14 Mar 2025
At a glance
- Originator Denali Therapeutics Inc
- Class Antibodies; Antidementias
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 28 Feb 2025 DNL 921 is still in preclinical trials for Alzheimer's disease in USA
- 28 Nov 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral)
- 01 Aug 2024 Denali Therapeutics terminates its licence for Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aß) in Alzheimer’s disease